Skip to main content

ESC Guidelines: Adenosine Response in Regular Narrow Complex Tachycardia (NCT)

Svt, avnrt, avrt

Adenosine Response in Regular Narrow Complex Tachycardia (NCT) πŸ«€⚡

Regular narrow complex tachycardia (QRS < 120 ms) is most commonly due to supraventricular tachycardias (SVTs). Adenosine is both a diagnostic and therapeutic agent in this setting because of its transient AV nodal block. Understanding the ECG response to adenosine is crucial for accurate rhythm diagnosis at the bedside, emergency department, and EP lab.

---

Mechanism of Action of Adenosine


Adenosine acts primarily on A1 receptors in the AV node, leading to:


Hyperpolarization of AV nodal tissue


Transient complete AV block


Very short half-life (≈ 10 seconds)



This makes adenosine ideal for unmasking atrial activity or terminating AV node–dependent tachycardias.



---


Why Adenosine Is Useful in Regular NCT


In regular NCT, the differential diagnosis includes:


AV nodal–dependent tachycardias


Atrial tachyarrhythmias with rapid ventricular response



Adenosine helps by answering one key question:


Is the AV node essential for maintenance of the tachycardia?



---


Adenosine Response Patterns in Regular NCT


1. Termination of Tachycardia


Diagnosis:


AVNRT (typical or atypical)


Orthodromic AVRT



ECG Response:


Sudden termination of tachycardia


Return to sinus rhythm



Interpretation:

The arrhythmia is AV node–dependent.



---


2. Transient AV Block With Ongoing Atrial Activity


Diagnosis:


Atrial flutter


Atrial tachycardia



ECG Response:


Ventricular rate slows or pauses


Atrial activity continues (flutter waves or P waves become visible)



Interpretation:

The arrhythmia is not AV node–dependent; AV node only conducts impulses.



---


3. No Effect or Minimal Effect


Diagnosis:


Sinus tachycardia


Some automatic atrial tachycardias



ECG Response:


Little or no change in rhythm


Possible brief slowing only



Interpretation:

Suggests enhanced automaticity, not reentry.



---


4. Transient Termination With Immediate Recurrence


Diagnosis:


Focal atrial tachycardia (adenosine-sensitive)



ECG Response:


Brief termination


Rapid recurrence of tachycardia



Interpretation:

Supports triggered activity or automatic focus, not AV nodal reentry.



---


Practical Diagnostic Algorithm (Regular NCT + Adenosine)


1. Regular NCT confirmed (QRS < 120 ms)



2. Vagal maneuvers attempted



3. Adenosine administered (6 mg → 12 mg IV rapid bolus)



4. Observe ECG response:


Terminates → AVNRT / AVRT


AV block unmasks atrial waves → Atrial flutter / AT


No effect → Sinus tachycardia or automatic AT






---


Important Clinical Pearls


Always record a continuous ECG strip during adenosine administration


Warn the patient about transient chest discomfort or flushing


Avoid adenosine in:


Irregular wide complex tachycardia


Pre-excited atrial fibrillation


Severe asthma (relative contraindication)





---


Summary Table


Adenosine Effect Likely Rhythm


Terminates tachycardia AVNRT / AVRT

AV block, atrial activity visible Atrial flutter / AT

Minimal or no effect Sinus tachycardia

Terminates then recurs Focal atrial tachycardia




---


Key Takeaway


Adenosine response is a powerful diagnostic tool in regular narrow complex tachycardia.

Termination implies AV node dependence, while persistence with exposed atrial activity points toward atrial arrhythmias.



---


For more cardiology-focused educational content, visit: drmusmanjaved.com



Comments

Popular posts from this blog

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB)

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB) Why this differentiation matters Brugada pattern is a malignant channelopathy associated with sudden cardiac death, while incomplete RBBB is usually a benign conduction variant. Mislabeling Brugada as iRBBB can be fatal; overcalling iRBBB as Brugada can lead to unnecessary anxiety and ICD implantation. --- 1. Basic Definitions Brugada ECG Pattern Primary repolarization abnormality Genetic sodium-channel disorder Characteristic ST-segment elevation in V1–V3 Risk of ventricular fibrillation and sudden death Incomplete RBBB (iRBBB) Depolarization abnormality Delay in right ventricular conduction Common in healthy individuals Usually asymptomatic and benign --- 2. ECG Morphology: Side-by-Side Comparison QRS Duration Brugada: QRS usually <120 ms iRBBB: QRS <120 ms, but with RBBB morphology --- V1–V2 Pattern (Key Differentiator) Brugada Pseudo-RBBB appearance ST elevation ≥2 mm ST segment is coved or saddleback Terminal QRS bl...

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.